Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 14, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The primary material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on March 10, 2006. The number of Ordinary Share ADRs held by the fund increased from 17,518,760 to 17,734,613. This transaction occurred at an average price of $54.00 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- Transaction Date: March 10, 2006.
- Entity Involved: GlaxoSmithKline US Retirement Savings Plan.
- Share Change: Increase of 215,853 Ordinary Share ADRs (from 17,518,760 to 17,734,613).
- Average Price: $54.00.
- Directors Affected: Dr. J P Garnier and Dr. T Yamada (as potential beneficiaries of the discretionary fund).